[1] subjected mice to I/R with 90 minutes ischemia followed by a 6-hour reperfusion. Serum alanine transaminase (ALT) levels increased to ∼5,000 IU/mL in our model and 33,000 IU/mL in the model of Kamo et al. Moreover, regarding the role of IL-1β, Kato et al.[4] reported that there was no difference in serum

ALT levels between wild-type and IL-1 receptor-deficient mice after hepatic I/R injury and suggested a limited role of IL-1β in causing hepatic I/R injury. We agree with the authors’ conclusion that the inflammasome plays a substantial role in hepatic I/R injury; however, the contribution of the inflammasome depends on the extent of injury and status of inflammatory responses; therefore, researchers should be aware of experimental disease conditions to discern the find protocol precise role of the inflammasome. Yoshiyuki Inoue, M.D.1,2 “
“Treatment of non-alcoholic fatty liver disease involves not only the management of the liver disease itself but the associated metabolic risk factors as well. However, no single treatment has been shown to be universally efficacious. Effective treatment regimens directed at both decreasing insulin resistance

as well as the processes of necroinflammation have been investigated and include lifestyle intervention, surgical treatment, and pharmacotherapy. Lifestyle modification, weight loss, and physical activity represent the cornerstone of treatment. Given the important MCE公司 role of insulin resistance in the pathophysiology BIBW2992 in vitro of non-alcoholic steatohepatitis, thiazolidinediones are used to improve insulin resistance. Ongoing large multicenter studies will provide information about long-term efficacy and safety of pioglitazone in patients with non-alcoholic steatohepatitis. Many other medications have shown promising results in the investigations using animal models and in preliminary pilot studies. Because the sample sizes of these studies

were relatively small and the durations were short, further validation is required. Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease and its incidence is increasing concomitantly with the increase in the prevalence of metabolic syndrome. NAFLD encompasses a broad pathological spectrum of disease from relatively benign simple steatosis to progressive non-alcoholic steatohepatitis (NASH), which is associated with necroinflammation and fibrosis.[1] The most worrisome feature of NASH is the potential progression to cirrhosis, hepatocellular carcinoma (HCC), and finally, mortality. Several factors such as insulin resistance, adipokines, endotoxins, hepatic iron overload, and oxidative stress are involved in the pathogenesis of NASH, although the precise etiological mechanisms of NAFLD/NASH have yet to be elucidated. Treatment of NAFLD involves not only the management of the liver disease itself but the associated metabolic risk factors as well.